[1]邵怡,王安平,王先令,等.肿瘤相关性低磷骨软化症的诊疗进展[J].国际内分泌代谢杂志,2017,37(02):112-115.[doi:10.3760/cma.j.issn.1673-4157.2017.02.011]
　Shao Yi,Wang Anping,Wang Xianling,et al.Diagnosis and treatment of tumor induced osteomalacia[J].International Journal of Endocrinology and Metabolism,2017,37(02):112-115.[doi:10.3760/cma.j.issn.1673-4157.2017.02.011]
点击复制

肿瘤相关性低磷骨软化症的诊疗进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年02期
页码:
112-115
栏目:
综述
出版日期:
2017-03-20

文章信息/Info

Title:
Diagnosis and treatment of tumor induced osteomalacia
作者:
邵怡; 王安平; 王先令; 母义明
100853 北京,解放军总医院内分泌科
Author(s):
Shao Yi; Wang Anping;  Wang Xianling;  Mu Yiming.
Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China
关键词:
肿瘤相关性低磷骨软化症;  代谢性骨病;  病理性骨折;  间叶组织肿瘤;  生长抑素
Keywords:
Tumor induced osteomalacia;  Metabolic bone disease;  Pathological fractures;  Mesenchymal tissue tumor;  Somatostatin
DOI:
10.3760/cma.j.issn.1673-4157.2017.02.011
摘要:
肿瘤相关性低磷骨软化症是一种由于肿瘤分泌过多的利磷因子,如成纤维细胞生长因子-23(FGF-23)等,引起肾脏排磷增多造成的获得性代谢性骨病。肿瘤多来源于间叶组织,位于骨或软组织内,位置隐匿。临床表现为随病程进展逐渐加重的骨骼疼痛、活动受限、肌无力等。骨X线摄片可见骨密度普遍降低,骨小梁影模糊。本病为一种少见病,临床表现复杂多变,患者就诊科室分散,因此误诊、误治率高。但是通过积极的定性和定位检查,明确定位肿瘤,手术全切后可以痊愈。
Abstract:
Tumor induced osteomalacia(TIO)is an acquired metabolic bone disease caused by tumors secreting high concentration of phosphatonins such as fibroblast growth factor-23(FGF-23),resulting in renal phosphate wasting. The tumors are derived from mesenchymal tissue in bone or soft tissues,and always located in obscure tissues. Clinical manifestations include progression of bone pain, activity limitation, muscle weakness,etc. Bone X-ray films show lower bone mineral density and fuzzy bone trabecular. Patients with TIO always look for medical care in various departments because of these complex manifestations. As a result, the rates of misdiagnosis and mistreatment are high previously. With multiple qualitative and positioning inspection, this disease can be clearly diagnosed and cured after tumor complete resection.

参考文献/References:

[1] 杨云建, 陈继营, 杨帆, 等. 11例瘤源性骨软化症的临床诊治分析[J]. 解放军医学院学报, 2014, 35(7):707-709.DOI:10.3969/j.issn.2095-5227.2014.07.017.
[2] Amblee A, Uy J, Senseng C,et al. Tumor-induced osteomalacia with normal systemic fibroblast growth factor-23 level[J].Clin Kidney J,2014,7(2):186-189. DOI: 10.1093/ckj/sfu004.
[3] Folpe AL, Fanburg-Smith JC, Billings SD,et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature[J].Am J Surg Pathol,2004,28(1):1-30.
[4] 郑桂玲,郝建华. 肿瘤相关性低血磷骨软化症误诊为滑膜皱襞综合征[J]. 临床误诊误治, 2016,29(1):59-61.DOI:10.3969/j.issn.1002-3429.2016.01.023.
[5] 贺莉,郑燕,章振林. 肿瘤性骨软化症3例并文献复习[J]. 中华骨质疏松和骨矿盐疾病杂志,2014,7(2):121-125.DOI:10.3969/j.issn.1674-2591.2014.02.004.
[6] Jonsson KB, Zahradnik R, Larsson T,et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia[J].N Engl J Med,2003,348(17):1656-1663.DOI: 10.1056/NEJMoa020881.
[7] Gattineni J, Bates C, Twombley K,et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1[J].Am J Physiol Renal Physiol,2009,297(2):F282-F291.DOI:10.1152/ajprenal.90742.2008.
[8] Berndt TJ, Schiavi S, Kumar R. “Phosphatonins” and the regulation of phosphorus homeostasis[J].Am J Physiol Renal Physiol,2005,289(6):F1170-F1182.DOI:10.1152/ajprenal.00072.2005.
[9] Imel EA, Peacock M, Pitukcheewanont P,et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia[J].J Clin Endocrinol Metab,2006,91(6):2055-2061.DOI: http://dx.doi.org/10.1210/jc.2005-2105.
[10] 巴建明,桑艳红,陆菊明,等.12例肿瘤性骨软化症的临床诊治及术后随访[J].中华内分泌代谢杂志,2011,27(1):19-23. DOI: 10.3760/cma.j.issn.1000-6699.2011.01.007.
[11] Bahrami A, Weiss SW, Montgomery E,et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia[J].Am J Surg Pathol,2009,33(9):1348-1354. DOI: 10.1097/PAS.0b013e3181aa2311.
[12] Wang XL, Mu YM. Emphasis should be placed on the diagnosis and therapy of tumor induced osteomalacia[J].Chin Med J(Engl),2011,124(2):163-165.
[13] Ledford CK, Zelenski NA, Cardona DM,et al. The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed [J].Clin Orthop Relat Res,2013,471(11):3618-3625. DOI: 10.1007/s11999-013-3178-1.
[14] 余卫,林强,张云庆,等.瘤源性骨质软化症的影像学表现及临床诊断价值 [J].中华放射学杂志,2006,40(6): 616-620.DOI:10.3760/j.issn:1005-1201.2006.06.013.
[15] Jiang Y, Xia WB, Xing XP,et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature[J].J Bone Miner Res,2012,27(9):1967-1975. DOI: 10.1002/jbmr.1642.
[16] Chong WH, Andreopoulou P, Chen CC,et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia[J].J Bone Miner Res,2013,28(6):1386-1398. DOI: 10.1002/jbmr.1881.
[17] 王颖倩,巴建明,王先令,等.颅面部肿瘤所致低磷软骨病 2 例并文献复习[J]. 解 放 军 医 学 院 学 报, 2013,34(4):405-407.DOI:10.3969/j.issn.2095-5227.2013.04.032.
[18] Palot Manzil FF, Bhambhvani PG, O'Malley JP. Evaluation of tumor-induced osteomalacia with 111In-pentetreotide scintigraphy[J].J Nucl Med Technol,2013,41(4):299-301. DOI: 10.2967/jnmt.113.126763.
[19] Naswa N, Sharma P, Kumar R,et al. Successful localization of residual culprit tumor in a case of tumor-induced osteomalacia using 68Ga-DOTANOC PET/CT[J].Clin Nucl Med,2013,38(8):639-640. DOI: 10.1097/RLU.0b013e318279eb13.
[20] Sahoo J, Balachandran K, Kamalanathan S,et al. Tumor(s)induced osteomalacia-a curious case of double trouble[J].J Clin Endocrinol Metab,2014,99(2):395-398. DOI: 10.1210/jc.2013-3791.
[21] Ovejero D, Collins MT. RAS in FGF23: another piece in the puzzle[J].J Clin Endocrinol Metab,2014,99(1):63-66. DOI: 10.1210/jc.2013-4290.
[22] 方凯彬,沈荣凯,张文明,等.低血磷性骨软化症七例报告[J].中国骨与关节杂志,2015,4(1):71-75.DOI: 10.3969/j.issn.2095-252X.2015.01.017.
[23] Jing H, Li F, Zhuang H,et al. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide(99mTc-HYNIC-TOC)whole body scan[J].Eur J Radiol,2013,82(11):2028-2034.DOI:10.1016/j.ejrad.2013.04.006.
[24] 谢燚, 李汉忠, 张寅生,等. 肾癌所致骨软化症一例报告及文献复习[J]. 中华泌尿外科杂志, 2011, 32(1):27-30.DOI:l0.3760/cma.j.issn.1000-6702.2011.01.011.
[25] Sun ZJ, Jin J, Qiu GX,et al. Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 caseswith extremity tumors[J].BMC Musculoskelet Disord,2015,16:43. DOI: 10.1186/s12891-015-0496-3.
[26] Geller JL, Khosravi A, Kelly MH,et al. Cinacalcet in the management of tumor-induced osteomalacia[J].J Bone Miner Res,2007,22(6):931-937.DOI:10.1359/jbmr.070304.
[27] Gore MO, Welch BJ, Geng W,et al. Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis[J].Kidney Int,2009,76(3):342-347. DOI: 10.1038/ki.2008.355.
[28] Chong WH, Molinolo AA, Chen CC,et al. Tumor-induced osteomalacia[J].Endocr Relat Cancer,2011,18(3):R53-R77. DOI: 10.1530/ERC-11-0006.
[29] Serafini EM, Pisarevsky AA, Plumet Garrido J,et al. Tumor-induced osteomalacia: rhinosinusal hemangiopericytoma[J].Medicina(B Aires),2013,73(1):39-42.
[30] 金京玉,孙飞,王刚,等.误诊为脊柱关节炎的低磷软骨病26例临 床 分 析[J].中 华 内 科 杂 志,2014,53( 11): 847-851.DOI:10.3760/cma.j.issn.0578-1426.2014.11.003.

相似文献/References:

[1]孔晶,王鸥,邢小平.狄诺塞麦治疗代谢性骨病的研究进展[J].国际内分泌代谢杂志,2016,36(05):334.[doi:10.3760/cma.j.issn.1673-4157.2016.05.13]
　Kong Jing,Wang Ou,Xing Xiaoping.Update on denosumab treatment in metabolic bone diseases[J].International Journal of Endocrinology and Metabolism,2016,36(02):334.[doi:10.3760/cma.j.issn.1673-4157.2016.05.13]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81471026) 通信作者:王先令,Email:wangxianling1972@sohu.com
更新日期/Last Update: 2017-03-20